School of Neuroscience and Psychology, University of Glasgow, Glasgow, United Kingdom.
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Mov Disord Clin Pract. 2024 Sep;11(9):1113-1124. doi: 10.1002/mdc3.14139. Epub 2024 Jun 19.
Dopaminergic responsiveness is a defining feature of Parkinson's disease (PD). However, there is limited information on how this evolves over time.
To examine serial dopaminergic responses, if there are distinct patterns, and which factors predict these.
We analyzed data from the Parkinson's Progression Markers Initiative on repeated dopaminergic challenge tests (≥24.5% defined as a definite response). Growth-mixture modeling evaluated for different response patterns and multinomial logistic regression tested for predictors of these clusters.
1525 dopaminergic challenge tests were performed in 336 patients. At enrolment, mean age was 61.2 years (SD 9.6), 66.4% were male and disease duration was 0.5 years (SD 0.5). 1 to 2 years after diagnosis, 48.0% of tests showed a definite response, but this proportion increased with longer disease duration (51.1-74.3%). We identified 3 response groups: "Striking" (n = 29, 8.7%); "Excellent" (n = 110; 32.7%) and "Modest" (n = 197, 58.6%). Significant differences were as follows: striking responders commenced treatment earlier (P = 0.02), were less likely to be on dopamine agonist monotherapy (P = 0.01), and had better cognition (P < 0.01) and activities of daily living (P = 0.01). Excellent responders had higher challenge doses (P = 0.03) and were more likely to be on combination therapy (P < 0.01).
Three distinct patterns of the dopaminergic response were observed. As the proportion of PD cases with definite dopa responsiveness increased over time, the initial treatment response may be an unreliable diagnostic aid.
多巴胺反应性是帕金森病(PD)的一个决定性特征。然而,关于其随时间如何演变的信息有限。
检查多巴胺反应的连续变化,如果存在不同的模式,以及哪些因素可以预测这些模式。
我们分析了帕金森病进展标志物倡议中重复多巴胺刺激测试的数据(≥24.5%定义为明确反应)。增长混合模型评估了不同的反应模式,多项逻辑回归检验了这些聚类的预测因素。
在 336 名患者中进行了 1525 次多巴胺刺激测试。入组时,平均年龄为 61.2 岁(标准差 9.6),66.4%为男性,疾病持续时间为 0.5 年(标准差 0.5)。在诊断后 1 至 2 年内,48.0%的测试显示出明确的反应,但随着疾病持续时间的延长,这一比例增加(51.1-74.3%)。我们确定了 3 种反应组:“显著”(n=29,8.7%);“优异”(n=110;32.7%)和“适度”(n=197,58.6%)。显著差异如下:显著反应者开始治疗的时间更早(P=0.02),不太可能单独使用多巴胺激动剂治疗(P=0.01),且认知功能(P<0.01)和日常生活活动(P=0.01)更好。优异反应者的刺激剂量更高(P=0.03),更有可能接受联合治疗(P<0.01)。
观察到三种不同的多巴胺反应模式。随着时间的推移,具有明确多巴胺反应性的 PD 病例比例增加,初始治疗反应可能不再是可靠的诊断辅助手段。